Aldose reductase: New insights for an old enzyme

Biomolecular Concepts

Volumn 2, Issue 1-2, 2011, Pages 103-114

  Ramana, Kota V ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

aldose reductase; cancer; diabetes; inflammation; oxidative stress; sepsis; uveitis

Indexed keywords

ANIMALIA; RODENTIA;

EID: 80054054044     PISSN: 18685021     EISSN: 1868503X     Source Type: Journal    
DOI: 10.1515/bmc.2011.002     Document Type: Review

References (109)

1. Hers HG. The mechanism of the transformation of glucose in fructose in the seminal vesicles. Biochim Biophys Acta 1956; 22: 202-3.
2. van Heyningen R. Formation of polyols by the lens of the rat with 'sugar' cataract. Nature 1959; 468: 194-5.
3. Kinoshita JH, Dvornik D, Kraml M, Gabbay KH. The effect of an aldose reductase inhibitor on the galactose-exposed rabbit lens. Biochim Biophys Acta 1968; 158: 472-5.
4. Varma SD, Kinoshita JH. Inhibition of lens aldose reductase by flavonoids - their possible role in the prevention of diabetic cataracts. Biochem Pharmacol 1976; 25: 2505-13.
5. Kinoshita JH, Fukushi S, Kador P, Merola LO. Aldose reductase in diabetic complications of the eye. Metabolism 1979; 28: 462-9.
6. van Heyningen R. Sugar alcohols in the pathogenesis of galactose and diabetic cataracts. Birth Defects Orig Artic Ser 1976; 12: 295-303.
7. Gabbay KH. The sorbitol pathway and the complications of diabetes. N Engl J Med 1973; 288: 831-6.
8. Brownlee M, Cerami A. The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 1981; 50: 385-432.
9. Oates PJ. Aldose reductase inhibitors and diabetic kidney disease. Curr Opin Investig Drugs 2010; 11: 402-17.
10. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications 2010; 24: 354-60.
11. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005; 26: 380-92.
12. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, Kokai Y. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 1995; 38: 255-61.
13. Lee AY, Chung SK, Chung SS. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA 1995; 92: 2780-4.
14. Shah VO, Scavini M, Nikolic J, Sun Y, Vai S, Griffith JK, Dorin RI, Stidley C, Yacoub M, Vander Jagt DL, Eaton RP, Zager PG. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab 1998; 83: 2886-91.
15. Hodgkinson AD, Søndergaard KL, Yang B, Cross DF, Millward BA, Demaine AG. Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy. Kidney Int 2001; 60: 211-8.
16. Ansari NH, Bhatnagar A, Fulep E, Khanna P, Srivastava SK. Trolox protects hyperglycemia-induced cataractogenesis in cultured rat lens. Res Commun Chem Pathol Pharmacol 1994; 84: 93-104.
17. Ansari NH, Srivastava SK. Allopurinol promotes and butylated hydroxy toluene prevents sugar-induced cataractogenesis. Biochem Biophys Res Commun 1990; 168: 939-43.
18. Bhatnagar A, Ansari NH, Zacarias A, Srivastava SK. Digital image analysis of cultured rat lens during oxidative stressinduced cataractogenesis. Exp Eye Res 1993; 57: 385-91.
19. Borhani DW, Harter TM, Petrash JM. The crystal structure of the aldose reductase. NADPH binary complex. J Biol Chem 1992; 267: 24841-7.
20. Vander Jagt DL, Kolb NS, Vander Jagt TJ, Chino J, Martinez FJ, Hunsaker LA, Royer RE. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta 1995; 1249: 117-26.
21. Srivastava S, Chandra A, Bhatnagar A, Srivastava SK, Ansari NH. Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem Biophys Res Commun 1995; 217: 741-6.
22. Srivastava S, Watowich SJ, Petrash JM, Srivastava SK, Bhatnagar A. Structural and kinetic determinants of aldehyde reduction by aldose reductase. Biochemistry 1999; 38: 42-54.
23. Dixit BL, Balendiran GK, Watowich SJ, Srivastava S, Ramana KV, Petrash JM, Bhatnagar A, Srivastava SK. Kinetic and structural characterization of the glutathione-binding site of aldose reductase. J Biol Chem 2000; 275: 21587-95.
24. Ramana KV, Dixit BL, Srivastava S, Balendiran GK, Srivastava SK, Bhatnagar A. Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry 2000; 39: 12172-80.
25. Ramana KV, Dixit BL, Srivastava S, Bhatnagar A, Balendiran GK, Watowich SJ, Petrash JM, Srivastava SK. Characterization of the glutathione binding site of aldose reductase. Chem Biol Interact 2001; 130-132: 537-48.
26. Srivastava S, Chandra A, Wang LF, Seifert WE Jr, DaGue BB, Ansari NH, Srivastava SK, Bhatnagar A. Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart. J Biol Chem 1998; 273: 10893-900.
27. Choudhary S, Srivastava S, Xiao T, Andley UP, Srivastava SK, Ansari NH. Metabolism of lipid derived aldehyde, 4-hydroxynonenal in human lens epithelial cells and rat lens. Invest Ophthalmol Vis Sci 2003; 44: 2675-82.
28. Srivastava S, Dixit BL, Cai J, Sharma S, Hurst HE, Bhatnagar A, Srivastava SK. Metabolism of lipid peroxidation product, 4-hydroxynonenal (HNE) in rat erythrocytes: role of aldose reductase. Free Radic Biol Med 2000; 29: 642-51.
29. Rittner HL, Hafner V, Klimiuk PA, Szweda LI, Goronzy JJ, Weyand CM. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest 1999; 103: 1007-13.
30. Forman HJ. Reactive oxygen species and α,β-unsaturated aldehydes as second messengers in signal transduction. Ann NY Acad Sci 2010; 1203: 35-44.
31. Uchida K. Lipid peroxidation and redox-sensitive signaling pathways. Curr Atheroscler Rep 2007; 9: 216-21.
32. Kutuk O, Basaga H. Apoptosis signaling by 4-hydroxynonenal: a role for JNK-c-Jun/AP-1 pathway. Redox Rep 2007; 12: 30-4.
33. Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J Biol Chem 2002; 277: 32063-70.
34. Ruef J, Liu SQ, Bode C, Tocchi M, Srivastava S, Runge MS, Bhatnagar A. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler Thromb Vasc Biol 2000; 20: 1745-52.
35. Ramana KV, Friedrich B, Bhatnagar A, Srivastava SK. Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-α in human lens epithelial cells. FASEB J 2003; 17: 315-7.
36. Ramana KV, Bhatnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-α-induced expression of adhesion molecules in endothelial cells. FASEB J 2004; 18: 1209-18.
37. Tammali R, Ramana KV, Singhal SS, Awasthi S, Srivastava SK. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res 2006; 66: 9705-13.
38. Singh R, White MA, Ramana KV, Petrash JM, Watowich SJ, Bhatnagar A, Srivastava SK. Structure of a glutathione conjugate bound to the active site of aldose reductase. Proteins 2006; 64: 101-10.
39. Ko BC, Lam KS, Wat NM, Chung SS. An (A-C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 1995; 44: 727-32.
40. Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neurol Neurosurg Psych 1998; 64: 213-6.
41. Kao YL, Donaghue K, Chan A, Knight J, Silink M. An aldose reductase intragenic polymorphism associated with diabetic retinopathy. Diabetes Res Clin Pract 1999; 46: 155-60.
42. Moczulski DK, Scott L, Antonellis A, Rogus JJ, Rich SS, Warram JH, Krolewski AS. Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in type 1 diabetes mellitus. Diabet Med 2000; 17: 111-8.
43. Neamat-Allah M, Feeney SA, Savage DA, Maxwell AP, Hanson RL, Knowler WC, El Nahas AM, Plater ME, Shaw J, Boulton AJ, Duff GW, Cox A. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in type 1 and type 2 diabetes mellitus. Diabet Med 2001; 18: 906-14.
44. Li Q, Xie P, Huang J, Gu Y, Zeng W, Song H. Polymorphisms and functions of the aldose reductase gene 59 regulatory region in Chinese patients with type 2 diabetes mellitus. Chin Med J (Engl) 2002; 115: 209-13.
45. Sivenius K, Pihlajamäki J, Partanen J, Niskanen L, Laakso M, Uusitupa M. Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. Diabetes Care 2004; 27: 2021-6.
46. Richeti F, Noronha RM, Waetge RT, de Vasconcellos JP, de Souza OF, Kneipp B, Assis N, Rocha MN, Calliari LE, Longui CA, Monte O, de Melo MB. Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy. Mol Vis 2007; 13: 740-5.
47. Ramana KV, Bhatnagar A, Srivastava S, Yadav UC, Awasthi S, Awasthi YC, Srivastava SK. Mitogenic responses of vascular smooth muscle cells to lipid peroxidation-derived aldehyde 4-hydroxy-trans-2-nonenal (HNE): role of aldose reductase-catalyzed reduction of the HNE-glutathione conjugates in regulating cell growth. J Biol Chem 2006; 281: 17652-60.
48. Sharma A, Sharma R, Chaudhary P, Vatsyayan R, Pearce V, Jeyabal PV, Zimniak P, Awasthi S, Awasthi YC. 4-Hydroxynonenal induces p53-mediated apoptosis in retinal pigment epithelial cells. Arch Biochem Biophys 2008; 480: 85-94.
49. Vaillancourt F, Fahmi H, Shi Q, Lavigne P, Ranger P, Fernandes JC, Benderdour M. 4-Hydroxynonenal induces apoptosis in human osteoarthritic chondrocytes: the protective role of glutathione-S-transferase. Arthritis Res Ther 2008; 10: R107.
50. Cerbone A, Toaldo C, Laurora S, Briatore F, Pizzimenti S, Dianzani MU, Ferretti C, Barrera G. 4-Hydroxynonenal and PPARγ ligands affect proliferation, differentiation, and apoptosis in colon cancer cells. Free Radic Biol Med 2007; 42: 1661-70.
51. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factorkB: its role in health and disease. J Mol Med 2004; 82: 434-48.
52. Srivastava SK, Ramana KV. Focus on molecules: nuclear factor-kB. Exp Eye Res 2009; 88: 2-3.
53. Mattie MD, McElwee MK, Freedman JH. Mechanism of copper-activated transcription: activation of AP-1, and the JNK/SAPK and p38 signal transduction pathways. J Mol Biol 2008; 383: 1008-18.
54. Tanos T, Marinissen MJ, Leskow FC, Hochbaum D, Martinetto H, Gutkind JS, Coso OA. Phosphorylation of c-Fos by members of the p38 MAPK family. Role in the AP-1 response to UV light. J Biol Chem 2005; 280: 18842-52.
55. Cho HJ, Kang JH, Kwak JY, Lee TS, Lee IS, Park NG, Nakajima H, Magae J, Chang YC. Ascofuranone suppresses PMAmediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms. Carcinogenesis 2007; 28: 1104-10.
56. Ramana KV, Reddy AB, Tammali R, Srivastava SK. Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages. Free Radic Biol Med 2007; 42: 1290-302.
57. Ramana KV, Bhatnagar A, Srivastava SK. Aldose reductase regulates TNF-α-induced cell signaling and apoptosis in vascular endothelial cells. FEBS Lett 2004; 570: 189-94.
58. Yadav UC, Ramana KV, Awasthi YC, Srivastava SK. Glutathione level regulates HNE-induced genotoxicity in human erythroleukemia cells. Toxicol Appl Pharmacol 2008; 227: 257-64.
59. Knoll N, Ruhe C, Veeriah S, Sauer J, Glei M, Gallagher EP, Pool-Zobel BL. Genotoxicity of 4-hydroxy-2-nonenal in human colon tumor cells is associated with cellular levels of glutathione and the modulation of glutathione S-transferase A4 expression by butyrate. Toxicol Sci 2005; 86: 27-35.
60. Dwivedi S, Sharma A, Patrick B, Sharma R, Awasthi YC. Role of 4-hydroxynonenal and its metabolites in signaling. Redox Rep 2007; 12: 4-10.
61. Rinaldi M, Barrera G, Aquino A, Spinsanti P, Pizzimenti S, Farace MG, Dianzani MU, Fazio VM. 4-Hydroxynonenal-induced MEL cell differentiation involves PKC activity translocation. Biochem Biophys Res Commun 2000; 272: 75-80.
62. Nitti M, Domenicotti C, d'Abramo C, Assereto S, Cottalasso D, Melloni E, Poli G, Biasi F, Marinari UM, Pronzato MA. Activation of PKC-β isoforms mediates HNE-induced MCP-1 release by macrophages. Biochem Biophys Res Commun 2002; 294: 547-52.
63. Castello L, Marengo B, Nitti M, Froio T, Domenicotti C, Biasi F, Leonarduzzi G, Pronzato MA, Marinari UM, Poli G, Chiarpotto E. 4-Hydroxynonenal signalling to apoptosis in isolated rat hepatocytes: the role of PKC-delta. Biochim Biophys Acta 2005; 1737: 83-93.
64. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003; 60: 6-20.
65. Bruunsgaard H, Poulsen HE, Pedersen BK, Nyyssonen K, Kaikkonen J, Salonen JT. Long-term combined supplementations with α-tocopherol and vitamin C have no detectable antiinflammatory effects in healthy men. J Nutr 2003; 133: 1170-3.
66. Bai J, Cederbaum AI. Overexpression of catalase in the mitochondrial or cytosolic compartment increases sensitivity of HepG2 cells to tumor necrosis factor-α-induced apoptosis. J Biol Chem 2000; 275: 19241-9.
67. Lin SJ, Shyue SK, Hung YY, Chen YH, Ku HH, Chen JW, Tam KB, Chen YL. Superoxide dismutase inhibits the expression of vascular cell adhesion molecule-1 and intracellular cell adhesion molecule-1 induced by tumor necrosis factor-α in human endothelial cells through the JNK/p38 pathways. Arterioscler Thromb Vasc Biol 2005; 25: 334-40.
68. Naito Y, Takano H, Yoshikawa T. Oxidative stress-related molecules as a therapeutic target for inflammatory and allergic diseases. Curr Drug Targets Inflamm Allergy 2005; 4: 511-5.
69. Sen CK, Roy S. Relief from a heavy heart: redox-sensitive NFkB as a therapeutic target in managing cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2005; 289: 17-9.
70. Jordan JA, Guo RF, Yun EC, Sarma V, Warner RL, Crouch LD, Senaldi G, Ulich TR, Ward PA. Role of IL-18 in acute lung inflammation. J Immunol 2001; 167: 7060-8.
71. Call GB, Husein OF, McIlmoil CJ, Adams A, Heckmann RA, Judd AM. Bovine adrenal cells secrete interleukin-6 and tumor necrosis factor in vitro. Gen Comp Endocrinol 2000; 118: 249-61.
72. Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med 1994; 180: 2365-70.
73. Miwa K, Nakamura J, Hamada Y, Naruse K, Nakashima E, Kato K, Kasuya Y, Yasuda Y, Kamiya H, Hotta N. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract 2003; 60: 1-9.
74. Murata M, Ohta N, Sakurai S, Alam S, Tsai J, Kador PF, Sato S. The role of aldose reductase in sugar cataract formation: aldose reductase plays a key role in lens epithelial cell death (apoptosis). Chem Biol Interact 2001; 130-132: 617-25.
75. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 1993; 21: 205-11.
76. Srivastava S, Ramana KV, Tammali R, Srivastava SK, Bhatnagar A. Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells. Diabetes 2006; 55: 901-10.
77. Kasuya Y, Ito M, Nakamura J, Hamada Y, Nakayama M, Chaya S, Komori T, Naruse K, Nakashima E, Kato K, Koh N, Hotta N. An aldose reductase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs. Diabetologia 1999; 42: 1404-9.
78. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994; 43: 1122-9.
79. Ramana KV, Friedrich B, Tammali R, West MB, Bhatnagar A, Srivastava SK. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes 2005; 54: 818-29.
80. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-κB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 2004; 53: 2910-20.
81. Tammali R, Saxena A, Srivastava SK, Ramana KV. Aldose reductase regulates vascular smooth muscle cell proliferation by modulating G1/S phase transition of cell cycle. Endocrinology 2010; 151: 2140-50.
82. Ramana KV, Tammali R, Srivastava SK. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells. Mol Cancer Ther 2010; 9: 813-24.
83. Ramana KV, Tammali R, Reddy AB, Bhatnagar A, Srivastava SK. Aldose reductase-regulated tumor necrosis factor-α production is essential for high glucose-induced vascular smooth muscle cell growth. Endocrinology 2007; 148: 4371-84.
84. Reddy AB, Ramana KV, Srivastava S, Bhatnagar A, Srivastava SK. Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-α via protein kinase C-δ and TNF-α converting enzyme in vascular smooth muscle cells. Endocrinology 2009; 150: 63-74.
85. Reddy AB, Srivastava SK, Ramana KV. Aldose reductase inhibition prevents lipopolysaccharide-induced glucose uptake and glucose transporter 3 expression in RAW264.7 macrophages. Int J Biochem Cell Biol 2010; 42: 1039-45.
86. Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. FASEB J 2005; 19: 795-7.
87. Ramana KV, Fadl AA, Tammali R, Reddy AB, Chopra AK, Srivastava SK. Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages. J Biol Chem 2006; 281: 33019-29.
88. Crimi E, Sica V, Slutsky AS, Zhang H, Williams-Ignarro S, Ignarro LJ, Napoli C. Role of oxidative stress in experimental sepsis and multisystem organ dysfunction. Free Radic Res 2006; 40: 665-72.
89. Sakaguchi S, Furusawa S. Oxidative stress and septic shock: metabolic aspects of oxygen-derived free radicals generated in the liver during endotoxemia. FEMS Immunol Med Microbiol 2006; 47: 167-77.
90. Ramana KV, Srivastava SK. Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages. Cytokine 2006; 36: 115-22.
91. Ramana KV, Willis MS, White MD, Horton JW, DiMaio JM, Srivastava D, Bhatnagar A, Srivastava SK. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 2006; 114: 1838-46.
92. Reddy AB, Srivastava SK, Ramana KV. Anti-inflammatory effect of aldose reductase inhibition in murine polymicrobial sepsis. Cytokine 2009; 48: 170-6.
93. Moore WC, Pascual RM. Update in asthma 2009. Am J Respir Crit Care Med 2010; 181: 1181-7.
94. Murphy DM, O'Byrne PM. Recent advances in the pathophysiology of asthma. Chest 2010; 137: 1417-26.
95. Yadav UC, Naura AS, Aguilera-Aguirre L, Ramana KV, Boldogh I, Sur S, Boulares HA, Srivastava SK. Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice. J Immunol 2009; 183: 4723-32.
96. Yadav UC, Ramana KV, Aguilera-Aguirre L, Boldogh I, Boulares HA, Srivastava SK. Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice. PLoS One 2009; 4: e6535.
97. Srivastava SK, Ramana KV. Aldose reductase inhibition for the treatment of asthma. Expert Rev Clin Immunol 2010; 6: 1-4.
98. Srivastava A, Rajappa M, Kaur J. Uveitis: mechanisms and recent advances in therapy. Clin Chim Acta 2010; 411: 1165-71.
99. Yadav UC, Srivastava SK, Ramana KV. Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2007; 48: 4634-42.
100. Yadav UC, Subramanyam S, Ramana KV. Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest Ophthalmol Vis Sci 2009; 50: 2276-82.
101. Kalariya NM, Shoeb M, Reddy AB, Zhang M, van Kuijk FJ, Ramana KV. Prevention of endotoxin-induced uveitis in rats by plant sterol guggulsterone. Invest Ophthalmol Vis Sci 2010; 51: 5105-13.
102. Yadav UC, Srivastava SK, Ramana KV. Understanding the role of aldose reductase in ocular inflammation. Curr Mol Med 2010; 10: 540-9.
103. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, Pessi MA, Prochilo T, Quadri A, Gatta G, de Braud F, Wils J. Colon cancer. Crit Rev Oncol Hematol 2010; 74: 106-33.
104. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 2009; 29: 2727-37.
105. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-14.e5.
106. Tammali R, Ramana KV, Srivastava SK. Aldose reductase regulates TNF-α-induced PGE2 production in human colon cancer cells. Cancer Lett 2007; 252: 299-306.
107. Tammali R, Reddy AB, Ramana KV, Petrash JM, Srivastava SK. Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. Carcinogenesis 2009; 30: 799-807.
108. Ramana KV, Srivastava SK. Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int J Biochem Cell Biol 2010; 42: 17-20.
109. Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ. Aldose reductase enzyme and its implication to major health problems of the 21st century. Curr Med Chem 2009; 16: 734-52.